Tibet AIM Pharm. Inc. (SHE:002826)

China flag China · Delayed Price · Currency is CNY
19.50
-0.02 (-0.10%)
Apr 30, 2026, 3:04 PM CST
84.83%
Market Cap 3.65B
Revenue (ttm) 670.32M
Net Income (ttm) 93.44M
Shares Out 187.27M
EPS (ttm) 0.51
PE Ratio 38.16
Forward PE n/a
Dividend 0.10 (0.51%)
Ex-Dividend Date Jun 24, 2025
Volume 7,078,753
Average Volume 4,946,353
Open 20.51
Previous Close 19.52
Day's Range 19.16 - 20.51
52-Week Range 10.40 - 26.83
Beta 0.53
RSI 39.23
Earnings Date Apr 28, 2026

About Tibet AIM Pharm.

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, severe infection, shock, cord injury, and brain, as well as coma, spinal cord injury, ce... [Read more]

Sector Healthcare
Founded 2003
Employees 403
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002826
Full Company Profile

Financial Performance

In 2025, Tibet AIM Pharm.'s revenue was 636.27 million, a decrease of -2.39% compared to the previous year's 651.88 million. Earnings were 92.58 million, an increase of 101.57%.

Financial Statements

News

There is no news available yet.